Results 241 to 250 of about 1,223,155 (304)

Synthetic Ligands of Myeloid C-Type Lectin Receptors. [PDF]

Chembiochem
Suri J, Lepenies B.
europepmc   +1 more source

Polymeric Nanoparticles for Precision Tumor Immunotherapy: Rational Design Strategies and Spatiotemporal Immune Activation. [PDF]

Int J Nanomedicine
Li D, Hu J, Cui Y, Li Q, Li X.
europepmc   +1 more source

Bacillus Calmette-Guérin as adjuvant platform enhances immunogenicity of conserved epitopes from structural proteins of SARS-CoV-2. [PDF]

Front Immunol
Santos AS, de Araújo LP, Orts DJB, da Costa HHM, Matteucci KC, Silva EN, Oliveira KC, Galdino G, Prudencio CR, Corsetti PP, de Almeida LA.   +10 more
europepmc   +1 more source

Simulation of synthetic health records for assessment of causal inference methods for vaccine efficacy

Velasco-Pardo V, Daines L, Katikireddi SV, Ritchie L, Robertson□ C, Simpson CR, McCowan C, Swallow B.   +7 more
europepmc   +1 more source

Bioactive lipid-derived nanoparticles for RNA delivery. [PDF]

Mater Today (Kidlington)
Long K, Yuan J, Zhang Y, Li Y, Zhong M, Wang W, Shi J.   +6 more
europepmc   +1 more source

The critical role of artificial intelligence and bioinformatics in accelerating peptide-based vaccine discovery for tackling global infectious diseases. [PDF]

Brief Bioinform
Tholo N, Markey G, Harrigan R, Pandey P, Prasad B, Barai RS, Gibson DS, Shukla P.   +7 more
europepmc   +1 more source

Recombinant and Synthetic Vaccines

, 2007
openaire   +1 more source

Synthetic oligosaccharide vaccines

, 1985
Vliegenthart, J.F.G., Snippe, H., Willers, J.M.N., Kamerling, J.P.   +3 more
openaire   +1 more source

T cell-mediated protection against lethal SARS-CoV-2 challenge by a synthetic long peptide vaccine targeting conserved CD4+ and CD8+ T cell epitopes

Gracht ETvd, Pardieck IN, Duikeren Sv, Rijn Pv, Veerkamp DM, de Graaf JF, Kwappenberg K, Kamerling IM, Kruithof AC, Plas JLvd, Linger ME, Horst JRB, Myeni SK, Krebber W, Hooftman L, Beenakker TJ, Arens R, Melief CJ, Wiekmeijer A.   +18 more
europepmc   +1 more source

Costs and impacts of vaccine preparedness investments for SARS-X pandemics

johnson R, Doohan P, Windus P, Torkelson A, Walker D, Whittaker C, Nedjati-Gilani G, Morgenstern C, Morel G, Miraldo M, Forchini G, Docrat F, Walker S, Gouglas D, Sabino A, Hauck K.   +15 more
europepmc   +1 more source